House Energy Committee Advances 29 Bills on AI, Drug Policy

Why It Matters

The House Energy and Commerce Committee advanced 29 bills during a markup on July 21, highlighting Republican priorities on artificial intelligence infrastructure, synthetic opioids, Medicare transparency and critical minerals. The session underscored bipartisan concern over electricity costs associated with AI data centers while advancing legislation on healthcare, energy, pipeline safety and drug enforcement.

The Big Picture

The full committee markup represented a consolidation of months of subcommittee work into a single day of rapid-fire votes. The bills cover energy policy, healthcare, drug enforcement, and national security, reflecting the committee's wide ranging jurisdiction. At the center sits tension over who's responsible for the cost of America's AI boom. In March 2026, President Trump convened a meeting of leading AI companies at the White House to sign the Ratepayer Protection Pledge, a voluntary commitment to shield households from electricity price hikes driven by surging data center demand.

However, skeptics questioned whether the pledge alone would solve the problem. The Brookings Institution has argued that the pledge "needs enforcement" and that voluntary commitments from Big Tech are insufficient without statutory backstops.

The committee advanced H.R. 9340, the Ratepayer Protection Act, along with H.R. 9339, the Affordable Innovation for the Grid Act. Both bills seek to protect consumers from electricity cost increases associated with expanding data center demand. The Ratepayer Protection Act previously advanced from the Energy Subcommittee by a 52-0 vote, according to Daily Energy Insider. Companion legislation, including H.R. 6633, the High-Capacity Grid Act, and H.R. 9335, the Advanced Transmission Technology to Reduce Rates Act, addresses transmission infrastructure needed to meet rising electricity demand.

The committee also advanced several bills addressing synthetic opioids. Those included H.R. 1266, the Combating Illicit Xylazine Act; H.R. 5880, the Fight Illicit Pill Presses Act; and H.R. 7970, the STOP Nitazenes Act. The legislation follows the Trump administration's decision to designate illicit fentanyl and certain precursor chemicals as weapons of mass destruction and reflects broader efforts to address emerging synthetic drugs. The Regulatory Review described congressional debate over xylazine and nitazenes as a case study in legislative delays amid a growing drug crisis

Healthcare legislation included H.R. 9392, the Medicare Advantage Cost Transparency Act, and H.R. 3514, the Improving Seniors' Timely Access to Care Act. The measures seek to increase transparency and reduce prior authorization delays in Medicare Advantage. The American Medical Association said more than 120 organizations have urged Congress that the "time for expeditious legislative action is now." Meanwhile, the Georgetown University Medicare Policy Initiative noted that recent administration regulations did not include some prior authorization reforms sought by patient advocates.

The committee also approved H.R. 5526, the Biosimilar Red Tape Elimination Act, and H.R. 9661, the Expedited Access to Biosimilars Act, as part of broader efforts to increase competition in the prescription drug market. The Biosimilars Council described the Red Tape Elimination Act as a "commonsense" approach to lowering drug costs through increased competition.

Critical minerals legislation also advanced. H.R. 9616, the Environmental Monitoring and Remediation Technology Assessment Initiative Act, and H.R. 9617, the Coordinating and Harnessing America's Recovery of Minerals Act, align with the administration's broader emphasis on strengthening domestic critical mineral supply chains. The Wilson Center has noted that the administration is treating critical minerals as a national security priority.

What They're Saying

Unlike an oversight hearing, the markup focused on debating amendments and voting on legislation. Committee Chair Rep. Brett Guthrie (R-Ky.) and Ranking Member Rep. Frank Pallone Jr. (D-N.J.) presided over consideration of the bills. During debate on the committee's AI-related legislation, members emphasized the need to ensure expanding AI infrastructure does not shift costs onto residential ratepayers. One committee document stated, "Over the next decade, demand for AI infrastructure will continue to grow exponentially across the world. We must ensure we're building AI infrastructure responsibly."

Rep. Kathy Castor (D-FL) argued that ratepayers should not subsidize electricity costs associated with large AI data centers. The American Pipeline Contractors Association endorsed H.R. 9338, the Pipeline Safety Authorization Act, saying it would improve pipeline safety while providing greater regulatory certainty.

Drug policy organizations expressed concerns about the criminal enforcement provisions. The Drug Policy Alliance argued that scheduling xylazine and nitazenes could harm people who unknowingly possess those substances. The R Street Institute and Drug Policy Alliance also warned of a "whack-a-mole" effect in which restrictions on one substance encourage traffickers to shift to another.

The committee considered at least 10 committee amendments during the session, with members including Tonko, Carter, James, and Kelly filing amendments on various bills. The Clerk and procedural staff managed the voting process.

Political Stakes

For the Trump administration, the markup validated its dual focus on protecting ratepayers while accelerating AI deployment. For Democrats, bills like the Ratepayer Protection Act offered rare common ground with Republicans, though some progressives remained skeptical of voluntary corporate pledges. For the healthcare industry, faster biosimilar approvals promise lower costs but threaten margins. For drug policy advocates, the opioid bills represent the administration's enforcement-first approach—one that civil liberties groups say risks harming vulnerable populations.

The Congressional Research Service flagged that Congress may examine PHMSA staffing on pipeline safety, which faces persistent shortfalls affecting the agency's ability to conduct inspections and revise regulations. This could complicate implementation of the Pipeline Safety Authorization Act.

Yes, but

Not all bills sailed through. The committee also advanced H.R. 7184 (PRESS Act), which would bar the federal government from using subpoenas or search warrants against journalists to force disclosure of confidential sources. The PRESS Act passed the House previously but stalled in the Senate. The Society of Professional Journalists National President Ashanti Blaize-Hopkins declared that federal legislation shielding journalists from compelled disclosure is "long overdue." Yet the bill faces uncertain prospects in the Republican-controlled Senate.

What's Next:

The approved legislation is now eligible for consideration by the full House. Committee action is one of the final steps before House floor consideration, although leadership ultimately determines when or whether individual bills receive votes.

The Bottom Line

The committee's July markup demonstrated the Trump administration's legislative priorities while exposing lingering fault lines over costs, enforcement, and corporate accountability.

Access the Legis1 platform for comprehensive political news, data, and insights.

Spot something wrong? Report an issue with this article